Literature DB >> 9837867

Expression of adhesion molecules by lp(a): a potential novel mechanism for its atherogenicity.

S Allen1, S Khan, S p Tam, M Koschinsky, P Taylor, M Yacoub.   

Abstract

Lp(a) is a major inherited risk factor for premature atherosclerosis. The mechanism of Lp(a) atherogenicity has not been elucidated, but likely involves both its ability to interfere with plasminogen activation and its atherogenic potential as a lipoprotein particle after receptor-mediated uptake. We demonstrate that Lp(a) stimulates production of vascular cell adhesion molecule 1 (VCAM-1) and E-selectin in cultured human coronary artery endothelial cells (HCAEC). This effect resulted from a rise in intracellular free calcium induced by Lp(a) and could be inhibited by the intracellular calcium chelator, BAPTA/AM. The involvement of the LDL and VLDL receptors in Lp(a) activation of HCAEC were ruled out since Lp(a) induction of adhesion molecules was not prevented by an antibody (IgGC7) to the LDL receptor or by receptor-activating protein, an antagonist of ligand binding to the VLDL receptor. Addition of alpha2-macroglobulin as well as treatment with heparinase, chondroitinase ABC, and sodium chlorate did not decrease levels of VCAM-1 and E-selectin stimulated by Lp(a), suggesting that neither the low density lipoprotein receptor-related protein nor cell-surface proteoglycans are involved in Lp(a)-induced adhesion molecule production. Neither does the binding site on HCAEC responsible for adhesion molecule production by Lp(a) appear to involve plasminogen receptors, as levels of VCAM-1 and E-selectin were not significantly decreased by the addition of glu-plasminogen, the lysine analog epsilon-aminocaproic acid, or by trans-4-(aminomethyl)-cyclohexanecarboxymethylic acid (tranexamic acid), which acts by binding to the lysine binding sites carried on the kringle structures in plasminogen. In contrast, recombinant apolipoprotein (a) [r-apo(a)] competed with Lp(a) and attenuated the expression of VCAM-1 and E-selectin. In summary, we have identified a calcium-dependent interaction of Lp(a) with HCAEC capable of inducing potent surface expression of VCAM-1 and E-selectin that does not appear to involve any of the known potential Lp(a) binding sites. Because leukocyte recruitment to the vessel wall appears to represent one of the important early events in atherogenesis, this newly described endothelial cell-activating effect of Lp(a) places it at a crucial juncture in the initiation of atherogenic disease and may lead to a better understanding of the role of Lp(a) in the vascular biology of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9837867     DOI: 10.1096/fasebj.12.15.1765

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  21 in total

1.  Mechanistic insights into Lp(a)-induced IL-8 expression: a role for oxidized phospholipid modification of apo(a).

Authors:  Corey A Scipione; Sera E Sayegh; Rocco Romagnuolo; Sotirios Tsimikas; Santica M Marcovina; Michael B Boffa; Marlys L Koschinsky
Journal:  J Lipid Res       Date:  2015-10-16       Impact factor: 5.922

2.  Elevated Lipoprotein(a) Levels Lower ABCA1 Cholesterol Efflux Capacity.

Authors:  Hagai Tavori; Alexandra M Fenton; Deanna L Plubell; Sara Rosario; Elisabeth Yerkes; Rayna Gasik; Joshua Miles; Paige Bergstrom; Jessica Minnier; Sergio Fazio; Nathalie Pamir
Journal:  J Clin Endocrinol Metab       Date:  2019-10-01       Impact factor: 5.958

3.  Lipoprotein(a) in atherosclerosis: from pathophysiology to clinical relevance and treatment options.

Authors:  Andreja Rehberger Likozar; Mark Zavrtanik; Miran Šebeštjen
Journal:  Ann Med       Date:  2020-06-08       Impact factor: 4.709

Review 4.  On the role of endothelial TRPC3 channels in endothelial dysfunction and cardiovascular disease.

Authors:  K Smedlund; M Bah; G Vazquez
Journal:  Cardiovasc Hematol Agents Med Chem       Date:  2012-09

Review 5.  Emerging Therapeutic Options for Lowering of Lipoprotein(a): Implications for Prevention of Cardiovascular Disease.

Authors:  Michael B Boffa
Journal:  Curr Atheroscler Rep       Date:  2016-12       Impact factor: 5.113

Review 6.  Lipoprotein(a) and atherosclerosis: new perspectives on the mechanism of action of an enigmatic lipoprotein.

Authors:  Marlys L Koschinsky
Journal:  Curr Atheroscler Rep       Date:  2005-09       Impact factor: 5.113

Review 7.  Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease?

Authors:  Michael B Boffa; Marlys L Koschinsky
Journal:  J Lipid Res       Date:  2015-12-08       Impact factor: 5.922

8.  Lipoprotein(a): biology and clinical importance.

Authors:  Sally P A McCormick
Journal:  Clin Biochem Rev       Date:  2004-02

Review 9.  Economic Evaluation of the PCSK9 Inhibitors in Prevention of the Cardiovascular Diseases.

Authors:  Parth Shah
Journal:  Curr Cardiol Rep       Date:  2018-05-19       Impact factor: 2.931

10.  Apolipoprotein(a), through its strong lysine-binding site in KIV(10'), mediates increased endothelial cell contraction and permeability via a Rho/Rho kinase/MYPT1-dependent pathway.

Authors:  Taewoo Cho; Yoojin Jung; Marlys L Koschinsky
Journal:  J Biol Chem       Date:  2008-09-05       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.